Shire
12:35 :
Shire slips as rivals production problems look set to ease -
Shire's treatment for Fabry disease benefited from Genzyme's troubles, but boom may be overShire has come under pressure on a renewed competitive threat to one of its key drugs.Its Replagal treatment for Fabry disease has seen a boost to its sales following ...
19:13 :
Shire hits a 'high' on hyperactivity drug hopes -
Although the market slouched back into the doldrums amid jitters over America's credit rating, investors rushed into Shire, sending the pharmaceutical company to an all-time high.
22:10 :
MARKET REPORT: Shire soars on dose of bid talk -
Hyperactive punters dosed up with shares of Shire as revived takeover rumours swept dealing rooms. The UK's third-largest drugs group closed 22p up at a 52-week peak of 2002p on hefty turnover of 36m.
19:05 :
Shire stages turnaround on latest deal -
Having helped keep the market on its sickbed earlier in the week, drug makers on Wednesday helped the large-caps stage a recovery as Shire shrugged off early scepticism about its latest acquisition.
10:22 :
Shire slips after $750m US wound healing deal -
Shire shares have fallen back after the pharmaceutical group announced a $750m cash acquisition in America.It is buying privately owned Advanced BioHealing, which makes a bio-engineered skin substitute used to treat slow healing foot ulcers. ...
10:14 :
Shire buys Advanced BioHealing for $750m -
Shire agrees to buy US-based Advanced BioHealing to gain access to Dermagraft, a skin substitute that assists in restoring damaged tissue, for $750m (£462m) in cash
18:37 :
AstraZeneca, Shire decline in London trade -
Equities markets in London were higher Thursday, as the
FTSE 100 added 0.03 percent to 6,069.9 and the
FTSE 250 gained 1 percent to 12,013.9 as the media sector and insurers saw gains, and most utilities were higher but banks were ...
19:03 :
Drug maker Shire sets new sales record -
Shire's product sales broke the $3bn barrier for the first time last year as the drug maker benefited from manufacturing problems at a US rival and increased sales of its hyperactivity medicine.
actualidad Shire -